Table of Content

1 Multivalent Influenza Vaccines Market Overview
1.1 Product Overview and Scope of Multivalent Influenza Vaccines
1.2 Multivalent Influenza Vaccines Segment by Type
1.2.1 Global Multivalent Influenza Vaccines Market Value Comparison by Type (2024-2034)
1.2.2 Trivalent Inactivated Influenza Vaccine (IIV3)
1.2.3 Trivalent Live Attenuated Vaccine (LAIV3)
1.2.4 Quadrivalent Inactivated Influenza Vaccine (IIV4)
1.3 Multivalent Influenza Vaccines Segment by Application
1.3.1 Global Multivalent Influenza Vaccines Market Value by Application: (2024-2034)
1.3.2 6 Months to 3 Years
1.3.3 Above 3 Years
1.4 Global Multivalent Influenza Vaccines Market Size Estimates and Forecasts
1.4.1 Global Multivalent Influenza Vaccines Revenue 2024-2034
1.4.2 Global Multivalent Influenza Vaccines Sales 2024-2034
1.4.3 Global Multivalent Influenza Vaccines Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Multivalent Influenza Vaccines Market Competition by Manufacturers
2.1 Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers (2024-2024)
2.2 Global Multivalent Influenza Vaccines Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Multivalent Influenza Vaccines Average Price by Manufacturers (2024-2024)
2.4 Global Multivalent Influenza Vaccines Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Multivalent Influenza Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multivalent Influenza Vaccines, Product Type & Application
2.7 Multivalent Influenza Vaccines Market Competitive Situation and Trends
2.7.1 Multivalent Influenza Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multivalent Influenza Vaccines Players Market Share by Revenue
2.7.3 Global Multivalent Influenza Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multivalent Influenza Vaccines Retrospective Market Scenario by Region
3.1 Global Multivalent Influenza Vaccines Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Multivalent Influenza Vaccines Global Multivalent Influenza Vaccines Sales by Region: 2024-2034
3.2.1 Global Multivalent Influenza Vaccines Sales by Region: 2024-2024
3.2.2 Global Multivalent Influenza Vaccines Sales by Region: 2024-2034
3.3 Global Multivalent Influenza Vaccines Global Multivalent Influenza Vaccines Revenue by Region: 2024-2034
3.3.1 Global Multivalent Influenza Vaccines Revenue by Region: 2024-2024
3.3.2 Global Multivalent Influenza Vaccines Revenue by Region: 2024-2034
3.4 North America Multivalent Influenza Vaccines Market Facts & Figures by Country
3.4.1 North America Multivalent Influenza Vaccines Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Multivalent Influenza Vaccines Sales by Country (2024-2034)
3.4.3 North America Multivalent Influenza Vaccines Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Multivalent Influenza Vaccines Market Facts & Figures by Country
3.5.1 Europe Multivalent Influenza Vaccines Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Multivalent Influenza Vaccines Sales by Country (2024-2034)
3.5.3 Europe Multivalent Influenza Vaccines Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multivalent Influenza Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific Multivalent Influenza Vaccines Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Multivalent Influenza Vaccines Sales by Country (2024-2034)
3.6.3 Asia Pacific Multivalent Influenza Vaccines Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Multivalent Influenza Vaccines Market Facts & Figures by Country
3.7.1 Latin America Multivalent Influenza Vaccines Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Multivalent Influenza Vaccines Sales by Country (2024-2034)
3.7.3 Latin America Multivalent Influenza Vaccines Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multivalent Influenza Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa Multivalent Influenza Vaccines Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Multivalent Influenza Vaccines Sales by Country (2024-2034)
3.8.3 Middle East and Africa Multivalent Influenza Vaccines Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multivalent Influenza Vaccines Sales by Type (2024-2034)
4.1.1 Global Multivalent Influenza Vaccines Sales by Type (2024-2024)
4.1.2 Global Multivalent Influenza Vaccines Sales by Type (2024-2034)
4.1.3 Global Multivalent Influenza Vaccines Sales Market Share by Type (2024-2034)
4.2 Global Multivalent Influenza Vaccines Revenue by Type (2024-2034)
4.2.1 Global Multivalent Influenza Vaccines Revenue by Type (2024-2024)
4.2.2 Global Multivalent Influenza Vaccines Revenue by Type (2024-2034)
4.2.3 Global Multivalent Influenza Vaccines Revenue Market Share by Type (2024-2034)
4.3 Global Multivalent Influenza Vaccines Price by Type (2024-2034)
5 Segment by Application
5.1 Global Multivalent Influenza Vaccines Sales by Application (2024-2034)
5.1.1 Global Multivalent Influenza Vaccines Sales by Application (2024-2024)
5.1.2 Global Multivalent Influenza Vaccines Sales by Application (2024-2034)
5.1.3 Global Multivalent Influenza Vaccines Sales Market Share by Application (2024-2034)
5.2 Global Multivalent Influenza Vaccines Revenue by Application (2024-2034)
5.2.1 Global Multivalent Influenza Vaccines Revenue by Application (2024-2024)
5.2.2 Global Multivalent Influenza Vaccines Revenue by Application (2024-2034)
5.2.3 Global Multivalent Influenza Vaccines Revenue Market Share by Application (2024-2034)
5.3 Global Multivalent Influenza Vaccines Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Sanofi
6.1.1 Sanofi Corporation Information
6.1.2 Sanofi Description and Business Overview
6.1.3 Sanofi Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Sanofi Multivalent Influenza Vaccines Product Portfolio
6.1.5 Sanofi Recent Developments/Updates
6.2 CSL
6.2.1 CSL Corporation Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.2.4 CSL Multivalent Influenza Vaccines Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.3.4 GSK Multivalent Influenza Vaccines Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Viatris
6.4.1 Viatris Corporation Information
6.4.2 Viatris Description and Business Overview
6.4.3 Viatris Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Viatris Multivalent Influenza Vaccines Product Portfolio
6.4.5 Viatris Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.5.4 AstraZeneca Multivalent Influenza Vaccines Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Hualan Bio
6.6.1 Hualan Bio Corporation Information
6.6.2 Hualan Bio Description and Business Overview
6.6.3 Hualan Bio Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Hualan Bio Multivalent Influenza Vaccines Product Portfolio
6.6.5 Hualan Bio Recent Developments/Updates
6.7 Changchun Institute of Biological
6.6.1 Changchun Institute of Biological Corporation Information
6.6.2 Changchun Institute of Biological Description and Business Overview
6.6.3 Changchun Institute of Biological Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Changchun Institute of Biological Multivalent Influenza Vaccines Product Portfolio
6.7.5 Changchun Institute of Biological Recent Developments/Updates
6.8 Sinovac
6.8.1 Sinovac Corporation Information
6.8.2 Sinovac Description and Business Overview
6.8.3 Sinovac Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Sinovac Multivalent Influenza Vaccines Product Portfolio
6.8.5 Sinovac Recent Developments/Updates
6.9 Bcht Biotechnology
6.9.1 Bcht Biotechnology Corporation Information
6.9.2 Bcht Biotechnology Description and Business Overview
6.9.3 Bcht Biotechnology Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Bcht Biotechnology Multivalent Influenza Vaccines Product Portfolio
6.9.5 Bcht Biotechnology Recent Developments/Updates
6.10 Jiangsu GDK
6.10.1 Jiangsu GDK Corporation Information
6.10.2 Jiangsu GDK Description and Business Overview
6.10.3 Jiangsu GDK Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Jiangsu GDK Multivalent Influenza Vaccines Product Portfolio
6.10.5 Jiangsu GDK Recent Developments/Updates
6.11 KM Biologics
6.11.1 KM Biologics Corporation Information
6.11.2 KM Biologics Multivalent Influenza Vaccines Description and Business Overview
6.11.3 KM Biologics Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.11.4 KM Biologics Multivalent Influenza Vaccines Product Portfolio
6.11.5 KM Biologics Recent Developments/Updates
6.12 ADIMMUNE Corporation
6.12.1 ADIMMUNE Corporation Corporation Information
6.12.2 ADIMMUNE Corporation Multivalent Influenza Vaccines Description and Business Overview
6.12.3 ADIMMUNE Corporation Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.12.4 ADIMMUNE Corporation Multivalent Influenza Vaccines Product Portfolio
6.12.5 ADIMMUNE Corporation Recent Developments/Updates
6.13 Aleph Biomedical
6.13.1 Aleph Biomedical Corporation Information
6.13.2 Aleph Biomedical Multivalent Influenza Vaccines Description and Business Overview
6.13.3 Aleph Biomedical Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Aleph Biomedical Multivalent Influenza Vaccines Product Portfolio
6.13.5 Aleph Biomedical Recent Developments/Updates
6.14 Shanghai Institute of Biological Products
6.14.1 Shanghai Institute of Biological Products Corporation Information
6.14.2 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Description and Business Overview
6.14.3 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
6.14.5 Shanghai Institute of Biological Products Recent Developments/Updates
6.15 Zhongyianke Biotech
6.15.1 Zhongyianke Biotech Corporation Information
6.15.2 Zhongyianke Biotech Multivalent Influenza Vaccines Description and Business Overview
6.15.3 Zhongyianke Biotech Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.15.4 Zhongyianke Biotech Multivalent Influenza Vaccines Product Portfolio
6.15.5 Zhongyianke Biotech Recent Developments/Updates
6.16 Wuhan Institute of Biological Products
6.16.1 Wuhan Institute of Biological Products Corporation Information
6.16.2 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Description and Business Overview
6.16.3 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales, Revenue and Gross Margin (2024-2024)
6.16.4 Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product Portfolio
6.16.5 Wuhan Institute of Biological Products Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multivalent Influenza Vaccines Industry Chain Analysis
7.2 Multivalent Influenza Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multivalent Influenza Vaccines Production Mode & Process
7.4 Multivalent Influenza Vaccines Sales and Marketing
7.4.1 Multivalent Influenza Vaccines Sales Channels
7.4.2 Multivalent Influenza Vaccines Distributors
7.5 Multivalent Influenza Vaccines Customers
8 Multivalent Influenza Vaccines Market Dynamics
8.1 Multivalent Influenza Vaccines Industry Trends
8.2 Multivalent Influenza Vaccines Market Drivers
8.3 Multivalent Influenza Vaccines Market Challenges
8.4 Multivalent Influenza Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Multivalent Influenza Vaccines Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Multivalent Influenza Vaccines Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Multivalent Influenza Vaccines Market Competitive Situation by Manufacturers in 2022
Table 4. Global Multivalent Influenza Vaccines Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global Multivalent Influenza Vaccines Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Multivalent Influenza Vaccines Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Multivalent Influenza Vaccines Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Multivalent Influenza Vaccines Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Multivalent Influenza Vaccines, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Multivalent Influenza Vaccines, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Multivalent Influenza Vaccines, Product Type & Application
Table 12. Global Key Manufacturers of Multivalent Influenza Vaccines, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Multivalent Influenza Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multivalent Influenza Vaccines as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Multivalent Influenza Vaccines Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Multivalent Influenza Vaccines Sales by Region (2024-2024) & (K Units)
Table 18. Global Multivalent Influenza Vaccines Sales Market Share by Region (2024-2024)
Table 19. Global Multivalent Influenza Vaccines Sales by Region (2024-2034) & (K Units)
Table 20. Global Multivalent Influenza Vaccines Sales Market Share by Region (2024-2034)
Table 21. Global Multivalent Influenza Vaccines Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2024-2024)
Table 23. Global Multivalent Influenza Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Multivalent Influenza Vaccines Revenue Market Share by Region (2024-2034)
Table 25. North America Multivalent Influenza Vaccines Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Multivalent Influenza Vaccines Sales by Country (2024-2024) & (K Units)
Table 27. North America Multivalent Influenza Vaccines Sales by Country (2024-2034) & (K Units)
Table 28. North America Multivalent Influenza Vaccines Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Multivalent Influenza Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Multivalent Influenza Vaccines Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Multivalent Influenza Vaccines Sales by Country (2024-2024) & (K Units)
Table 32. Europe Multivalent Influenza Vaccines Sales by Country (2024-2034) & (K Units)
Table 33. Europe Multivalent Influenza Vaccines Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Multivalent Influenza Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Multivalent Influenza Vaccines Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Multivalent Influenza Vaccines Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific Multivalent Influenza Vaccines Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific Multivalent Influenza Vaccines Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Multivalent Influenza Vaccines Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Multivalent Influenza Vaccines Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Multivalent Influenza Vaccines Sales by Country (2024-2024) & (K Units)
Table 42. Latin America Multivalent Influenza Vaccines Sales by Country (2024-2034) & (K Units)
Table 43. Latin America Multivalent Influenza Vaccines Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Multivalent Influenza Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa Multivalent Influenza Vaccines Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Multivalent Influenza Vaccines Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Multivalent Influenza Vaccines Sales (K Units) by Type (2024-2024)
Table 51. Global Multivalent Influenza Vaccines Sales (K Units) by Type (2024-2034)
Table 52. Global Multivalent Influenza Vaccines Sales Market Share by Type (2024-2024)
Table 53. Global Multivalent Influenza Vaccines Sales Market Share by Type (2024-2034)
Table 54. Global Multivalent Influenza Vaccines Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Multivalent Influenza Vaccines Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2024-2024)
Table 57. Global Multivalent Influenza Vaccines Revenue Market Share by Type (2024-2034)
Table 58. Global Multivalent Influenza Vaccines Price (US$/Unit) by Type (2024-2024)
Table 59. Global Multivalent Influenza Vaccines Price (US$/Unit) by Type (2024-2034)
Table 60. Global Multivalent Influenza Vaccines Sales (K Units) by Application (2024-2024)
Table 61. Global Multivalent Influenza Vaccines Sales (K Units) by Application (2024-2034)
Table 62. Global Multivalent Influenza Vaccines Sales Market Share by Application (2024-2024)
Table 63. Global Multivalent Influenza Vaccines Sales Market Share by Application (2024-2034)
Table 64. Global Multivalent Influenza Vaccines Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Multivalent Influenza Vaccines Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2024-2024)
Table 67. Global Multivalent Influenza Vaccines Revenue Market Share by Application (2024-2034)
Table 68. Global Multivalent Influenza Vaccines Price (US$/Unit) by Application (2024-2024)
Table 69. Global Multivalent Influenza Vaccines Price (US$/Unit) by Application (2024-2034)
Table 70. Sanofi Corporation Information
Table 71. Sanofi Description and Business Overview
Table 72. Sanofi Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Sanofi Multivalent Influenza Vaccines Product
Table 74. Sanofi Recent Developments/Updates
Table 75. CSL Corporation Information
Table 76. CSL Description and Business Overview
Table 77. CSL Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. CSL Multivalent Influenza Vaccines Product
Table 79. CSL Recent Developments/Updates
Table 80. GSK Corporation Information
Table 81. GSK Description and Business Overview
Table 82. GSK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. GSK Multivalent Influenza Vaccines Product
Table 84. GSK Recent Developments/Updates
Table 85. Viatris Corporation Information
Table 86. Viatris Description and Business Overview
Table 87. Viatris Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Viatris Multivalent Influenza Vaccines Product
Table 89. Viatris Recent Developments/Updates
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. AstraZeneca Multivalent Influenza Vaccines Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Hualan Bio Corporation Information
Table 96. Hualan Bio Description and Business Overview
Table 97. Hualan Bio Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Hualan Bio Multivalent Influenza Vaccines Product
Table 99. Hualan Bio Recent Developments/Updates
Table 100. Changchun Institute of Biological Corporation Information
Table 101. Changchun Institute of Biological Description and Business Overview
Table 102. Changchun Institute of Biological Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Changchun Institute of Biological Multivalent Influenza Vaccines Product
Table 104. Changchun Institute of Biological Recent Developments/Updates
Table 105. Sinovac Corporation Information
Table 106. Sinovac Description and Business Overview
Table 107. Sinovac Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Sinovac Multivalent Influenza Vaccines Product
Table 109. Sinovac Recent Developments/Updates
Table 110. Bcht Biotechnology Corporation Information
Table 111. Bcht Biotechnology Description and Business Overview
Table 112. Bcht Biotechnology Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Bcht Biotechnology Multivalent Influenza Vaccines Product
Table 114. Bcht Biotechnology Recent Developments/Updates
Table 115. Jiangsu GDK Corporation Information
Table 116. Jiangsu GDK Description and Business Overview
Table 117. Jiangsu GDK Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Jiangsu GDK Multivalent Influenza Vaccines Product
Table 119. Jiangsu GDK Recent Developments/Updates
Table 120. KM Biologics Corporation Information
Table 121. KM Biologics Description and Business Overview
Table 122. KM Biologics Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. KM Biologics Multivalent Influenza Vaccines Product
Table 124. KM Biologics Recent Developments/Updates
Table 125. ADIMMUNE Corporation Corporation Information
Table 126. ADIMMUNE Corporation Description and Business Overview
Table 127. ADIMMUNE Corporation Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. ADIMMUNE Corporation Multivalent Influenza Vaccines Product
Table 129. ADIMMUNE Corporation Recent Developments/Updates
Table 130. Aleph Biomedical Corporation Information
Table 131. Aleph Biomedical Description and Business Overview
Table 132. Aleph Biomedical Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Aleph Biomedical Multivalent Influenza Vaccines Product
Table 134. Aleph Biomedical Recent Developments/Updates
Table 135. Shanghai Institute of Biological Products Corporation Information
Table 136. Shanghai Institute of Biological Products Description and Business Overview
Table 137. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Shanghai Institute of Biological Products Multivalent Influenza Vaccines Product
Table 139. Shanghai Institute of Biological Products Recent Developments/Updates
Table 140. Zhongyianke Biotech Corporation Information
Table 141. Zhongyianke Biotech Description and Business Overview
Table 142. Zhongyianke Biotech Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. Zhongyianke Biotech Multivalent Influenza Vaccines Product
Table 144. Zhongyianke Biotech Recent Developments/Updates
Table 145. Wuhan Institute of Biological Products Corporation Information
Table 146. Wuhan Institute of Biological Products Description and Business Overview
Table 147. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 148. Wuhan Institute of Biological Products Multivalent Influenza Vaccines Product
Table 149. Wuhan Institute of Biological Products Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Multivalent Influenza Vaccines Distributors List
Table 153. Multivalent Influenza Vaccines Customers List
Table 154. Multivalent Influenza Vaccines Market Trends
Table 155. Multivalent Influenza Vaccines Market Drivers
Table 156. Multivalent Influenza Vaccines Market Challenges
Table 157. Multivalent Influenza Vaccines Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Multivalent Influenza Vaccines
Figure 2. Global Multivalent Influenza Vaccines Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Multivalent Influenza Vaccines Market Share by Type in 2022 & 2034
Figure 4. Trivalent Inactivated Influenza Vaccine (IIV3) Product Picture
Figure 5. Trivalent Live Attenuated Vaccine (LAIV3) Product Picture
Figure 6. Quadrivalent Inactivated Influenza Vaccine (IIV4) Product Picture
Figure 7. Global Multivalent Influenza Vaccines Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 8. Global Multivalent Influenza Vaccines Market Share by Application in 2022 & 2034
Figure 9. 6 Months to 3 Years
Figure 10. Above 3 Years
Figure 11. Global Multivalent Influenza Vaccines Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 12. Global Multivalent Influenza Vaccines Market Size (2024-2034) & (US$ Million)
Figure 13. Global Multivalent Influenza Vaccines Sales (2024-2034) & (K Units)
Figure 14. Global Multivalent Influenza Vaccines Average Price (US$/Unit) & (2024-2034)
Figure 15. Multivalent Influenza Vaccines Report Years Considered
Figure 16. Multivalent Influenza Vaccines Sales Share by Manufacturers in 2022
Figure 17. Global Multivalent Influenza Vaccines Revenue Share by Manufacturers in 2022
Figure 18. The Global 5 and 10 Largest Multivalent Influenza Vaccines Players: Market Share by Revenue in 2022
Figure 19. Multivalent Influenza Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 20. Global Multivalent Influenza Vaccines Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 21. North America Multivalent Influenza Vaccines Sales Market Share by Country (2024-2034)
Figure 22. North America Multivalent Influenza Vaccines Revenue Market Share by Country (2024-2034)
Figure 23. United States Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 24. Canada Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 25. Europe Multivalent Influenza Vaccines Sales Market Share by Country (2024-2034)
Figure 26. Europe Multivalent Influenza Vaccines Revenue Market Share by Country (2024-2034)
Figure 27. Germany Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. France Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. U.K. Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. Italy Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. Russia Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Asia Pacific Multivalent Influenza Vaccines Sales Market Share by Region (2024-2034)
Figure 33. Asia Pacific Multivalent Influenza Vaccines Revenue Market Share by Region (2024-2034)
Figure 34. China Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. Japan Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. South Korea Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. India Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. Australia Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. China Taiwan Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Southeast Asia Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. Latin America Multivalent Influenza Vaccines Sales Market Share by Country (2024-2034)
Figure 42. Latin America Multivalent Influenza Vaccines Revenue Market Share by Country (2024-2034)
Figure 43. Mexico Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Brazil Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Argentina Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Middle East & Africa Multivalent Influenza Vaccines Sales Market Share by Country (2024-2034)
Figure 47. Middle East & Africa Multivalent Influenza Vaccines Revenue Market Share by Country (2024-2034)
Figure 48. Turkey Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. Saudi Arabia Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. UAE Multivalent Influenza Vaccines Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Global Sales Market Share of Multivalent Influenza Vaccines by Type (2024-2034)
Figure 52. Global Revenue Market Share of Multivalent Influenza Vaccines by Type (2024-2034)
Figure 53. Global Multivalent Influenza Vaccines Price (US$/Unit) by Type (2024-2034)
Figure 54. Global Sales Market Share of Multivalent Influenza Vaccines by Application (2024-2034)
Figure 55. Global Revenue Market Share of Multivalent Influenza Vaccines by Application (2024-2034)
Figure 56. Global Multivalent Influenza Vaccines Price (US$/Unit) by Application (2024-2034)
Figure 57. Multivalent Influenza Vaccines Value Chain
Figure 58. Multivalent Influenza Vaccines Production Process
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed